{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["BoYu Intelligent Health Innovation Laboratory, Hangzhou, 311100, P. R. China."],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1163013"],"scientific_name":["Mus musculus"],"tag":["xref:PubMed:40596188"],"long_description":["Osteosarcoma (OS) is a severe malignancy affecting children and adolescents, with limited effective treatments leading to poor outcomes. This study explored the potential of sporoderm-removed Ganoderma lucidum spores (RGLS) as a novel therapeutic agent against OS and elucidated its mechanism of action. Our in vivo and in vitro experiments showed that RGLS significantly inhibited S-180 OS cell proliferation, colony formation, and migration, while simultaneously inducing apoptosis. Multi-omics analysis revealed that RGLS disrupted glycerophospholipid metabolism by upregulating lysophosphatidylcholine (LysoPC) levels through phospholipase A2 (PLA2)-mediated pathways. Co-culture assays further demonstrated that RGLS promoted the endocytosis of macrophage-derived Pla2g7 protein into S-180 cells, enhancing its anti-cancer effects. Additionally, RGLS modulated the cellular fatty acid profile and suppressed the β-oxidation of long-chain fatty acids, leading to energy depletion in OS cells. These findings provide a novel view of the multi-targeted mechanisms of RGLS, positioning it as a promising candidate for OS therapy. Overall design: We administered RGLS prophylactically to BALB/c nude mice and then injected them subcutaneously with S-180 cells to evaluate RGLS's tumor-inhibiting effects. We then extracted tissues from three model samples and three RGLS processed samples for RNA-seq."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores via targeting glycerophospholipid and fatty acid Metabolism","description":"Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores via targeting glycerophospholipid and fatty acid Metabolism","dates":{"last_updated":"2025-09-24","first_public":"2025-07-17"},"accession":"PRJNA1163013","cross_references":{"GEO":["GSE277633"],"taxon":["10090"],"PubMed":["40596188"]}}